Ask the Experts: Managing non-small-cell lung cancer with acquired resistance to EGF receptor and ALK inhibitors

2013 ◽  
Vol 2 (1) ◽  
pp. 23-26
Author(s):  
Siow-Ming Lee ◽  
Judy King
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egf Receptor ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

2012 ◽  
Vol 18 (22) ◽  
pp. 6219-6226 ◽  
Author(s):  
Junko Tanizaki ◽  
Isamu Okamoto ◽  
Takafumi Okabe ◽  
Kazuko Sakai ◽  
Kaoru Tanaka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
Her Family ◽  
Alk Positive

scholarly journals Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation

2020 ◽  
Vol 16 (21) ◽  
pp. 1537-1547
Author(s):  
Fumio Imamura ◽  
Madoka Kimura ◽  
Yukihiro Yano ◽  
Masahide Mori ◽  
Hidekazu Suzuki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Egfr Mutation ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Clinical Trial Registration

Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer (NSCLC). As the hazards ratio of overall survival in comparison with first-generation EGFR-tyrosine kinase inhibitors was almost similar between FLAURA and ARCHER 1050, salvage use of osimertinib is still a treatment option. Patients & methods: We retrospectively analyzed the clinical courses of EGFR mutation-positive NSCLC patients who were potential candidates for salvage osimertinib. Results: Among 524 patients enrolled from five hospitals, 302 patients underwent biopsy, with 52.6% detection rate of T790M. Osimertinib was administered in 93.6% of the T790M-positive patients. The overall response rate and median progression-free survival time of osimertinib were calculated with 147 patients, to be 55.6% and 17.2 months, respectively. Conclusion: Osimertinib is active for T790M-driven acquired resistance in EGFR-mutant NSCLC, but the detection of T790M was unsatisfactory. Clinical Trial Registration: UMIN000028989 (UMIN Clinical Trials Registry)

Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors

Neurology ◽  
2019 ◽  
Vol 93 (5) ◽  
pp. 217-219
Author(s):  
Alessia Pellerino ◽  
Lucio Buffoni ◽  
Roberta Rudà ◽  
Riccardo Soffietti
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastases ◽  
Complete Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors

Abstract 39: APOBEC3A drives acquired resistance to targeted therapies in non small cell lung cancer

2021 ◽  
Author(s):  
Hideko Isozaki ◽  
Ammal Abbasi ◽  
Naveed Nikpour ◽  
Adam Langenbucher ◽  
Wenjia Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

2019 ◽  
Vol 13 (10) ◽  
pp. 1019-1028 ◽  
Author(s):  
Niki Karachaliou ◽  
Jordi Codony-Servat ◽  
Jillian Wilhelmina Paulina Bracht ◽  
Masaoki Ito ◽  
Martyna Filipska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document